HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2007; **22**: 583–584.

Author Index

Ahl, J., 455
Akkaya, C., 515
Akwa, Y., 189
Alam, F., 129
Alciati, A., 33
Allain, H., 189
Andreoli, S., 149
Anttila, S., 211
Arita, S., 27
Arranz, B., 11
Asai, K., 97
Ashim, S., 129

Badyal, D. K., 477
Bahk, W.-M., 351
Balasubramaniam, K., 445
Barrett, S. P., 437, 529
Baune, B. T., 1
Bellantuono, C., 121
Bennett, D., 129
Bentué-Ferrer, D., 189
Beraudi, A., 75
Bersani, G., 103
Bijl, S., 157
Binder, C. E., 307
Bisaga, A., 41
Blanc, O., 373
Block, R. I., 135
Böcker, K. E., 157
Boidi, G., 299
Borkowska, A., 407
Bosanac, P., 223
Brambilla, F., 33
Brousse, G., 373
Brunelle, C., 437
Burrows, G., 223

Caciagli, F., 75
Caliskan, S., 1
Campbell, Z., 427
Cangur, S., 515
Canter, P. H., 265
Canuso, C. M., 326
Carlsson, A., 315
Centeno, M., 11
Centorrino, F., 455
Chandler, M. D., 81
Chi-Ming, L., 173
Chiappelli, M., 75
Cho, B.-H., 501
Choi, J.-E., 501
Chong, S.-A., 217
Choudhary, P. C., 445
Chue, P., 307
Cincotta, S. L., 455
Conti, C. M., 75
Conti, P., 75
Curran, S., 329

D'Arminio Monforte, A., 33
Darredeau, C., 529
Davis, P. C., 469
de Bruin, E. A., 157
De Luca, V., 463
de Osaba, M. J. M., 389
de-Melo-Neto, V. L., 231
del Moral, E., 11
Deswal, R. S., 477
DeVane, C. L., 469
Di Nicola, M., 149
Dinan, T., 397
Doyle, R., 75
Drozdz, W., 407
Dueñas, R. M., 11
Dunlop, B. W., 241

Earleywine, M., 167
Echizenya, M., 365
Ehret, M. J., 49
Eker, S. S., 67
Ennis, D. J., 469
Erdinc, S., 67
Ernst, E., 265
Escolar, G., 389

Feige, B., 567
Ferro, M., 299
Fiebich, B. L., 567
Figueroa, C., 469
Fisk, J. E., 81, 537
Freire, R. C., 231

Gómez-Gil, E., 389
Gallo, L., 33
Garawi, F., 41
Garlow, S. J., 241
Garvey, N., 491
Gastó, C., 389
Gentile, S., 121
Gherardelli, S., 103
Glue, P., 505
Gulliver, A. H., 455

Hänninen, K., 211
Hallam, K., 223
Hamer-Maansson, J. E., 469
Haney, M., 41
Haskell, C. F., 199, 559
Heinz, A., 89
Heishman, S. J., 89
Herpfer, I., 567
Hewlett, P., 339
Hichwa, R. D., 135
Hori, H., 483
Houston, J. P., 455
Huak, C. Y., 217
Hueber, T., 373
Hurme, M., 211
Hwang, R., 463

Illi, A., 211

Jackson, P. A., 559
James, J. E., 549
Janiri, L., 149
Jardin, B., 529
Jerrell, J. M., 361
Jolles, J., 289
Jon, D.-I., 351
Jovanovski, D., 427
Joyce, E., 445
Jung, I.-K., 501

Kampman, O., 211
Kang, S.-G., 501
Karim, S., 329
Kasper, S., 245
Katila, H., 211
Katzev, M., 567
Keane, M. A., 549
Kenemans, J. L., 157
Kennedy, D. O., 199, 559
Kennedy, J. L., 463
Khosla, P., 477
Kim, W., 501
Kim, L., 501
King, A. L., 231
Kinon, B. J., 455
Kirli, S., 67, 515
Kissling, W., 505
Knight, B. T., 241
Koeppel, J. A., 135
Kokkalis, J., 381
Kujawa, M., 326
Kurlender, S., 223

Copyright © 2007 John Wiley & Sons, Ltd.

Kusanagi, H., 365

Lachaux, B., 373
Lambert, T., 217
Laws, K. R., 381
Lee, S.-Y., 351
Lee, H.-J., 501
Lee, M.-S., 501
Lee, M.-S., 501
Lehtimäki, T., 211
Leinonen, E., 211
Lemoine, P., 373
Leonard, B. E., 253
Leung, C.-M., 17
Levin, G. M., 49
Licastro, F., 75
Lieb, K., 567
Lieberman, J. A., 463
Llorca, P.-M., 373
Looby, A., 167
Lopes, F. L., 231
Lui, S., 108

Magnotta, V. A., 135
Mahendran, R., 217
Mahmoud, R., 326
Manktelow, T., 223
Martín-Santos, R., 389
Martinotti, G., 149
Matreja, P. S., 477
Mattila, K. M., 211
Mauri, P. L., 199
Mbaya, P., 129
McIntyre, R. S., 361
Meary, A., 373
Medori, R., 505
Melkersson, K. I., 328
Mellado, C., 33
Meltzer, H. Y., 463
Meyers, A. L., 455
Mezzasalma, M. A., 231
Middleton, L., 54
Migliarese, G., 121
Min, K. J., 351
Mishima, K., 365
Mitoma, M., 483
Miyamoto, K., 483
Montgomery, C., 81, 537
Moolchan, E. T., 89
Morishita, S., 27
Moroni, N., 149
Mortimer, A. M., 445
Moser, U., 245
Mouret, J., 373
Müller, D. J., 463
Murphy, P. N., 81
Murphy, P., 537
Myers, C. S., 89

Nakamura, J., 483
Narasimhan, M., 49
Nardi, A. E., 231
Nascimento, I., 231
Navinés, R., 389
Ng, C., 217
Ninan, P. T., 241
Norman, T., 223

O'Grada, C., 397
O'Leary, D. S., 135
Ohkubo, T., 365
Orlandi, V., 103

Padilla, M., 41
Pae, C.-U., 351
Paik, J.-W., 501
Pancheri, P., 103
Pandina, G. J., 326
Papp, L., 241
Park, Y.-M., 501
Parrott, A. C., 423
Pek, E., 217
Pesaresi, L., 103
Pihl, R. O., 437, 529
Pjrek, E., 245
Poli, A., 75
Ponto, L. B., 135
Porcellini, E., 75
Pozzi, G., 149
Prinzo, R. S., 307

Ramirez, N., 11
Rathinavelu, A., 49
Romanelli, R., 149
Rontu, R., 211
Rybakowski, J. K., 407

Salavert, J., 11
Saleem, P. T., 445
San, L., 11
Sarandol, A., 67, 515
Sarandol, E., 67
Satoh, K., 365
Scholey, A. B., 199, 559
Schultz, S. K., 135
Shimada, Y., 97
Shimizu, T., 365
Simpson, S., 505
Smith, A., 339
Smith, M. A., 469
Soares-Filho, G. L., 231
Soetens, E., 279
Stening, G., 315
Subramaniam, M., 217
Sugita, A., 483
Sullivan, M. A., 41

Tanaka, Y., 97
Tang, W.-K., 17
Taylor, R. C., 89
Theunissen, E., 289
Timdahl, K., 315
Todder, D., 1
Tumini, E., 75

Ueda, H., 97
Ueda, N., 483
Umene, W., 483
Ungavri, G. S., 173
Ungvari, G. S., 17

Valença, A. M., 231
van Leeuwen, C., 289
van Oers, A., 289
Vatansever, E., 67
Veras, A. B., 231
Verbaten, M. N., 157
Voderholzer, U., 567
Volavka, J., 463
Vuurman, E., 289

Wai-Kwong, T., 173
Wareing, M., 81, 537
Waters, A. J., 89
Watkins, G. L., 135
Weiss, P. S., 241
Weng, Y.-z., 17
Wesnes, K., 223
Winkler, D., 245
Winter, H. R., 469

Xiang, Y.-t., 17

Yong-Zhen, W., 173
Yoon, B.-H., 351
Yoshida, S., 97
Yoshimura, R., 483
Youssef, E., 326
Yu-Tao, X., 173

Zakzanis, K. K., 427
Zeeuws, I., 279
Zin, W. A., 231
Zun, L., 455

Copyright © 2007 John Wiley & Sons, Ltd.

DOI: 10.1002/hup

HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2007; **22**: 585–586.

Keyword Index

5-HT_{1A} receptors, 389

acute, 559
acute agitation, 455
addiction, 529
adjunctive therapy, 1
adults, 361
aging, 365
alcohol, 157, 437
alertness, 339
alternative reinforcer, 41
Alzheimer's disease, 75
amisulpride, 445
anorexia nervosa, 223
anti-psychotics, 97
anticholinergic medication, 173
antidepressant, 1, 27
antidepressant treatment, 67
antidepressants, 121, 245
antihistamine, 289
antipsychotic, 307
antipsychotic agents, 211
antipsychotic treatment, 515
antipsychotics, 361, 463
antiretroviral therapy, 33
anxiety, 567
anxiety disorder, 231
apathy, 167
attention, 89, 135, 199, 397, 559
attention deficit disorder, 529
attentional blink, 89
atypical antipsychotic, 505
atypical antipsychotics, 103, 299

benzodiazepine, 365
bipolar mania, 455
body mass index, 217
brain, 157
brain imaging, 135
buspirone, 389

caffeine, 339, 483, 549
caffeine withdrawal, 339, 549
cardiovascular, 129
cardiovascular effects, 361
cerebrovascular effects, 361
CGI-Severity, 307
China, 17, 173
cholinesterase inhibitors, 189
chronic drinking, 157
cigarette smoking, 41, 483
citalopram, 477
clinical trials, 189
clonazepam, 27
clozapine, 17, 217
coffee, 231
cognition, 567
cognitive decline, 75
cognitive disorders, 189
cognitive function, 265, 445
cognitive performance, 339
COMT, 211
consolidation, 279
cotinine, 483
craving, 41, 149

D-amphetamine, 279
database analysis, 515
depression, 27, 167, 477, 483, 567
diabetes mellitus, 373
diagnosis, 231
diazepam, 365
dissociation, 365
divalproex, 469
dopamine, 373
dosage, 27
dose initiation, 299
driving, 289
drug response, 211
dual diagnosis, 149

ecstasy, 81, 381, 427, 537
effectiveness, 515
escitalopram, 245
ethnicity, 217
event related potential, 157
executive function, 397
extrapyramidal symptoms (EPS), 315

family history, 27
first-episode psychosis, 11
free recall, 279

G protein, 501
G51S polymorphism, 75
gamma-aminobutyric acid, 241
geriatric, 505
Ginkgo, 199
Ginko biloba, 265, 559
glucid metabolism, 373

haplotype, 463
happiness, 167
healthy, 559
healthy subjects, 265
heart rate, 437
herbal medicine, 265
HIV infection, 33
hormonal response, 389
HTR2C, 463
hydroxyzine, 289
hypertension, 217

IM olanzapine, 455
indinavir, 49
information processing speed, 81
inhibition, 397
intramuscular, 505

Korean, 351

long-acting, 505
low dose, 407

maintenance of effect, 307
major depression, 1, 33, 245, 389
major depressive disorder, 67, 129, 351
major malformations, 121
marijuana, 135
MCI, 189
MDMA, 381, 427, 537
medication diversion, 529
medication misuse, 529
memory, 189, 199, 381, 537, 559
meta-analysis, 381, 427
methamphetamine, 167
methylenedioxymethamphetamine, 381
methylphenidate, 529
mood, 199
motor activity, 1
multi-drug resistance gene, 49

naltrexone, 149
natural killer cells, 33
neural cell adhesion molecule, 97
neurokinin-1-receptor, 567
neuroleptics, 373
neuropeptides, 567
neuropsychological testing, 445
neuropsychology, 427
neurotoxicity, 381
nicotine, 89

Copyright © 2007 John Wiley & Sons, Ltd.

olanzapine, 445
orally disintegrating olanzapine, 11
orally disintegrating risperidone tablets, 307
oxcarbazepine, 149
oxidative stress, 67

P-glycoprotein, 49
panic attacks, 231
paroxetine, 483
paroxetine CR, 351
perception, 89
PET, 135
pharmacogenetics, 463
pharmacokinetics, 469
phosphatidylcholine, 199
phosphatidylserine, 199
polydipsia, 103
polymorphism, 211, 501
polysialic acid, 97
polysubstance, 529
predictor, 27
pregnancy, 121
prescription patterns, 17, 173
progressive ratio, 41
protracted withdrawal, 149
psychomotor function, 365
psychostimulants, 189
purine nucleoside phosphorylase, 75

quetiapine, 1, 103, 223, 299, 315, 469

reboxetine, 67
remission, 351
respiration, 231
respiratory test, 231
response, 351
retrieval, 279
review, 427
rifampin, 49
risperidone, 407, 505
rupatadine, 289

safety, 289
satisfaction with life, 167
schizoaffective disorder, 299, 455
schizophrenia, 17, 97, 103, 173, 211, 217, 299, 361, 397, 407, 445, 455, 463, 501, 505, 515
schizotaxia, 407
sedation, 437
selective GABA reuptake inhibitor, 241
selective serotonin inhibitors (SRIs), 121
self-administration, 41
sertraline, 67, 477
serum, 97
set shifting, 397
sick leave, 245
sleep, 1, 537, 549
sleepiness, 365
social anxiety disorder, 241
standard olanzapine tablets, 11
stimulation, 437
subjective well-being, 167
substance P, 567
substantial weight gain, 11

tardive dyskinesia, 373, 501
tiagabine, 241
tobacco deprivation, 89
tolerability, 299, 315, 469
transition, 307
treatment resistance, 217

valproic acid, 469
venlafaxine, 49, 67
venlafaxine XL, 129
verb generation, 157
verbal memory, 279

wakefulness, 549
weight gain, 463
western blotting, 97
withdrawal reversal, 549
working memory, 81, 397

young, 559

Copyright © 2007 John Wiley & Sons, Ltd.

Human Psychopharmacology
Clinical and Experimental

CO-EDITORS

Stephen Curran
Wakefield, UK
E-mail: steve.curran@swyt.nhs.uk

C. Lindsay DeVane
Charleston, USA
E-mail: devanel@musc.edu

EDITORIAL BOARD

Christer Allgulander
Huddinge, Sweden

David Baldwin
Southampton, UK

Manel Barbanoj de Rodriguez
Barcelona, Spain

Michael Berk
Geelong, Australia

Michel Bourin
Nantes, France

Ted Dinan
Cork, Ireland

Louise Dye
Leeds, UK

Peter Haddad
Manchester, UK

Brian H. Harvey
Potchefstroom, South Africa

Ian Hindmarch
Guildford, UK

Yul Iskander
Jakarta Pusat, Indonesia

Jan M. Keppel-Hesselink
Witten, Germany

Brian E. Leonard
Galway, Ireland

Toshitaka Nabeshima
Nagoya, Japan

Pradeep J. Nathan
Cambridge, UK

Petra Netter
Giessen, Germany

Trevor Norman
Heidelberg, Australia

Gregory Oxenkrug
Boston, USA

Andy Parrott
Swansea, UK

Jair C. Soares
San Antonio, USA

Kazuhiko Yanai
Sendai, Japan

Lakshmi Yatham
Vancouver, Canada

Allan H. Young
Newcastle-upon-Tyne, UK

FORMER EDITORS-IN-CHIEF

Guy Edwards (Founder Editor-in-Chief) 1986–1993
Brian Leonard 1994–1999
Ian Hindmarch 2000–2005

AIMS AND SCOPE

Human Psychopharmacology provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of especial interest to the editors and readers of the journal:

- All aspects of clinical psychopharmacology
- Efficacy and safety studies of novel and standard psychotropic drugs
- Studies of the adverse effects of psychotropic drugs
- Effects of psychotropic drugs on physiological processes
- Geriatric and Paediatric psychopharmacology
- Ethical and psychosocial aspects of drug use and misuse
- Psychopharmacological aspects of sleep and chronobiology
- Neuroimaging and psychoactive drugs
- Phytopharmacology and psychoactive substances
- Drug treatment of neurological disorders
- Mechanisms of action of psychotropic drugs
- Ethnopsychopharmacology
- Pharmacogenetic aspects of mental illness and drug response
- Psychometrics: psychopharmacological methods and experimental design

Human Psychopharmacology comprises Original Articles, Short Communications (not exceeding 1500 words), Reviews, Letters to the Editor (not exceeding 500 words), and Book Reviews, Editorials are by invitation but suggestions from readers are welcome.

EDITORIAL POLICY

The Editorial policy is to publish contributions on all aspects of psychopharmacology relevant to human experimental research and clinical medicine. *Human Psychopharmacology* is a multi-disciplinary journal that covers all aspects from clinical and social issues to experimental laboratory based studies that are of relevance to clinical psychopharmacology. All articles are strictly refereed and only those meeting acceptable ethical standards governing experimentation on humans or animals will be considered for publication. The editors are particularly pleased to consider publishing the proceedings of symposia as supplements to the journal providing they meet the strict editorial criteria. It is the intention of the Editors to publish contributions within three to six months from the date of final acceptance.

Human Psychopharmacology

Subscriptions

Human Psychopharmacology (Print ISSN 0885-6222; Online ISSN 1099-1077 at Wiley InterScience, www.interscience.wiley.com) is published bi-monthly plus one additional issue in April and one in August (total 8 issues) by John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, UK.

Subscription Rates

Volume 22 2007 8 issues

Print only: US$ 1505.00
Electronic only: US$ 1505.00
A combination price of US$1656.00 includes the subscription in both print and electronic formats.

To subscribe, please contact Journals Subscriptions Department, John Wiley & Sons, Ltd., 1 Oldlands Way, Bognor Regis, West Sussex PO22 9SA, UK.
Tel: +44 (0) 1243 843335,
Fax: +44 (0) 1243 843232,
e-mail: cs-journals@wiley.co.uk

Sample Copies

If you are interested in subscribing, you may obtain a free sample copy by contacting John Wiley & Sons, Ltd. at the above address.

Services

Advertisements

Advertisement Sales Department, John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, UK.
Tel: +44 (0)1243 770254
Fax: +44 (0)1243 770432
e-mail: adsales@wiley.co.uk

Reprints (minimum quantity 100 copies)

Reprints Co-ordinator, John Wiley & Sons, Ltd., The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, UK.
Tel: +44 (0) 1243 770515
Fax: +44 (0) 1243 770144
E-mail: reprints@wiley.co.uk

General Enquiries

Tel: +44 (0) 1243 779777,
Fax: +44 (0) 1243 775878.

Copyright

Copyright © 2007 John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, UK.
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except as described below, without the permission in writing of the Publisher.

Copying of articles is not permitted except for personal and internal use, to the extent permitted by national copyright law, or under the terms of a licence issued by the national Reproduction Rights Organization (such as Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 9HE, UK or Copyright Clearance Center Inc., 27 Congress Street, Salem, MA 01970, USA). The price per copy is $30.00. Requests for permission for other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale, and other enquiries should be addressed to the Publisher.

Statements and opinions expressed in the articles and communications are those of the individual contributors and not the statements and opinions of John Wiley & Sons, Ltd. Wiley assumes no responsibility or liability for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained herein. Wiley expressly disclaims any implied warranties of merchantability or fitness for a particular purpose. If expert assistance is required, the services of a competent professional person should be sought.

Abstracting and Indexing

Human Psychopharmacology is covered by the following abstracting and indexing services: Biological Abstracts® (Thomson ISI), BIOSIS Previews® (Thomson ISI), CAB Abstracts® (CABI), Cambridge Scientific Abstracts (CSA/CIG), Chemical Abstracts Service/ SciFinder (ACS), CSA Biological Sciences Database (CSA/CIG), CSA Environmental Sciences & Pollution Management Database (CSA/CIG), Current Abstracts (EBSCO), Current Awareness in Biological Sciences (Elsevier), Current Contents®/Life Sciences (Thomson ISI), EMBASE/Excerpta Medica (Elsevier), Index Medicus/MEDLINE/PubMed (NLM), Journal Citation Reports/Science Edition (Thomson ISI), Mental Health Abstracts (Kluwer), Neuroscience Citation Index™ (Thomson ISI), Psychological Abstracts/PsycINFO (APA), Science Citation Index Expanded™ (Thomson ISI), Science Citation Index® (Thomson ISI), SCOPUS (Elsevier), SIIC Databases (Sociedad Iberoamericana de Informacion Cientifica), Web of Science® (Thomson ISI).

Production Information

For manuscripts that have been accepted for publication, please. contact:

Jenna Brown
e-mail: jebrown@wiley.co.uk

Production Details

Printed on acid-free paper
Typeset by Thomson Press (India) Ltd.
Printed and bound in Great Britain by
Bell & Bain Ltd., Glasgow

Identification Statement

Human Psychopharmacology (ISSN 08856222) is published monthly except in the months of February, May, September and November by John Wiley & Sons, Ltd., The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, UK. Annual Subscription price US$900.00. Air freight and mailing in the USA by Publications Expediting Inc., 200 Meacham Ave., Elmont NY 11003. Periodical Postage paid at Jamaica NY 11431.
POSTMASTER please send address changes to *Human Psychopharmacology*, Publications Expediting Inc., 200 Meacham Ave., Elmont NY 11003.

Delivery Terms and Legal Title

Prices include delivery of print journals to the recipient's address. Delivery terms are Delivered Duty Unpaid (DDU); the recipient is responsible for paying any import duty or taxes. Legal title passes to the customer on despatch by our distributors.

CONTENTS

Volume 22 Issue Nos 1–8

HUMAN PSYCHOPHARMACOLOGY

Issue No. 1 January 2007

Research Articles

Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression: **B. T. Baune, S. Caliskan and D. Todder** 1

Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients: **B. Arranz, L. San, R. M. Dueñas, M. Centeno, N. Ramirez, J. Salavert and E. del Moral** 11

Clinical correlates of clozapine prescription for schizophrenia in China: **Y. Xiang, Y. Weng, C.-M. Leung, W.-K. Tang and G. S. Ungvari** 17

Possible predictors of response to clonazepam augmentation therapy in patients with protracted depression: **S. Morishita and S. Arita** 27

Major depression-related immunological changes and combination antiretroviral therapy in HIV-seropositive patients: **A. Alciati, L. Gallo, A. D'Arminio Monforte, F. Brambilla and C. Mellado** 33

Effects of alternative reinforcer and craving on the choice to smoke cigarettes in the laboratory: **A. Bisaga, M. Padilla, F. Garawi, M. A. Sullivan and M. Haney** 41

Short Report

Venlafaxine induces P-glycoprotein in human Caco-2 cells: **M. J. Ehret, G. M. Levin, M. Narasimhan and A. Rathinavelu** 49

Book Review

Clinical Guide to the Diagnosis and Treatment of Mental Disorders: **L. Middleton** 54

Current Awareness 55

Issue No. 2 March 2007

Research Article

Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative–antioxidative systems: **A. Sarandol, E. Sarandol, S. S. Eker, S. Erdinc, E. Vatansever and S. Kirli** 67

Short Report

The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients: **E. Tumini, E. Porcellini, M. Chiappelli, C. M. Conti, A. Beraudi, A. Poli, F. Caciagli, R. Doyle, P. Conti and F. Licastro** 75

Research Articles

Information processing speed in ecstasy (MDMA) users: **M. Wareing, J. E. Fisk, C. Montgomery, P. N. Murphy and M. D. Chandler** 81

Effect of tobacco deprivation on the attentional blink in rapid serial visual presentation: **A. Heinz, A. J. Waters, R. C. Taylor, C. S. Myers, E. T. Moolchan and S. J. Heishman** 89

Alteration in serum neural cell adhesion molecule in patients of schizophrenia: **Y. Tanaka, S. Yoshida, Y. Shimada, H. Ueda and K. Asai** 97

Short Communication
Atypical Antipsychotics and Polydipsia: A Cause or A Treatment?: **G. Bersani, L. Pesaresi, V. Orlandi, S. Gherardelli and P. Pancheri** 103

Book Review
Substance Use Disorders. A Practical Guide (Second Edition): **S. Lui** 108

Current Awareness in Human Psychopharmacology 109

Issue No. 3 April 2007

Review
Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review: **C. Bellantuono, G. Migliarese and S. Gentile** 121

Research Articles
Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder: **P. Mbaya, F. Alam, S. Ashim and D. Bennett** 129

Effects of smoking marijuana on focal attention and brain blood flow: **D. S. O'Leary, R. I. Block, J. A. Koeppel, S. K. Schultz, V. A. Magnotta, L. B. Ponto, G. L. Watkins and R. D. Hichwa** 135

High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients: **G. Martinotti, M. Di Nicola, R. Romanelli, S. Andreoli, G. Pozzi, N. Moroni and L. Janiri** 149

Effects of chronic drinking on verb generation: an event related potential study: **S. Bijl, E. A. de Bruin, K. E. Böcker, J. L. Kenemans and M. N. Verbaten** 157

The impact of methamphetamine use on subjective well-being in an Internet survey: preliminary findings: **A. Looby and M. Earleywine** 167

Exploring the clinical and social determinants of prescribing anticholinergic medication for Chinese patients with schizophrenia: **X. Yu-Tao, W. Yong-Zhen, L. Chi-Ming, T. Wai-Kwong and G. S. Ungavri** 173

Current Awareness in Human Psychopharmacology 181

Issue No. 4 June 2007

Review
Treatment of the mild cognitive impairment (MCI): **H. Allain, D. Bentué-Ferrer and Y. Akwa** 189

Research Articles
Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine: **D. O. Kennedy, C. F. Haskell, P. L. Mauri and A. B. Scholey** 199

Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia: **A. Illi, O. Kampman, K. Hänninen, S. Anttila, K. M. Mattila, H. Katila, R. Rontu, M. Hurme, T. Lehtimäki and E. Leinonen** 211

Metabolic differences between Asian and Caucasian patients on clozapine treatment: **M. Subramaniam, C. Ng, S.-A. Chong, R. Mahendran, T. Lambert, E. Pek and C. Y. Huak** 217

An open-label study of quetiapine in anorexia nervosa: **P. Bosanac, S. Kurlender, T. Norman, K. Hallam, K. Wesnes, T. Manktelow and G. Burrows** 223

Caffeine and 35% carbon dioxide challenge tests in panic disorder: **A. E. Nardi, A. M. Valença, F. L. Lopes, V. L. de-Melo-Neto, R. C. Freire, A. B. Veras, I. Nascimento, A. L. King, G. L. Soares-Filho, M. A. Mezzasalma and W. A. Zin** 231

Tiagabine for social anxiety disorder: **B. W. Dunlop, L. Papp, S. J. Garlow, P. S. Weiss, B. T. Knight and P. T. Ninan** 241

Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria: **D. Winkler, E. Pjrek, U. Moser and S. Kasper** 245

Book Review
Depression and physical illness: **B. E. Leonard** 253

Erratum 255

Current Awareness in Human Psychopharmacology 257

Issue No. 5 July 2007

Review
Ginkgo biloba is not a smart drug: an updated systematic review of randomised clinical trials testing the nootropic effects of *G. biloba* extracts in healthy people: **PH Canter and E. Ernst** 265

Research Articles
Verbal memory performance improved via an acute administration of D-amphetamine: **I. Zeeuws and E. Soetens** 279

Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers: **E. Vuurman, E. Theunissen, A. van Oers, C. van Leeuwen and J. Jolles** 289

Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open study: **G. Boidi and M. Ferro** 299

Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets: **P. Chue, R. S. Prinzo and C. E. Binder** 307

Review
An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms: **K. Timdahl, A. Carlsson and G. Stening** 315

Letter to the Editor
Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia: **G. J. Pandina, C. M. Canuso, E. Youssef, M. Kujawa and R. Mahmoud** 326

Author's response: **K. I. Melkersson** 328

Book Review
Improving Medication Adherence—how to talk to patients about their medications: **S. Karim and S. Curran** 329

Current Awareness in Human Psychopharmacology 331

Issue No. 6 August 2007

Research Articles
Effects of repeated doses of caffeine on performance and alertness: new data and secondary analyses: **P. Hewlett and A. Smith** 339

Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea: **C.-U. Pae, W.-M. Bahk, D.-I Jon, S.-Y. Lee, B.-H. Yoon and K. J. Min** 351

Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications: **J. M. Jerrell and R. S. McIntyre** 361

Dissociation between objective psychomotor impairment and subjective sleepiness after diazepam administration in the aged people: **M. Echizenya, K. Mishima, K. Satoh, H. Kusanagi, T. Ohkubo and T. Shimizu** 365

Tardive dyskinesia and glucid metabolism: **G. Brousse, A. Meary, J. Mouret, O. Blanc, T. Hueber, P. Lemoine, P.-M. Llorca and B. Lachaux** 373

Review
Ecstasy (MDMA) and memory function: a meta-analytic update: **K. R. Laws and J. Kokkalis** 381

Research Article
Hormonal response to buspirone is not impaired in major depression: **R. Navinés, E. Gómez-Gil, R. Martín-Santos, M. J. M. de Osaba, G. Escolar and C. Gastó** 389

Review
Executive function in schizophrenia: what impact do antipsychotics have?: **C. O'Grada and T. Dinan** 397

Research Article
Long-term administration of the low-dose risperidone in schizotaxia subjects: **J. K. Rybakowski, W. Drozdz and A. Borkowska** 407

Erratum 413

Current Awareness in Human Psychopharmacology 415

Issue No. 7 October 2007

Editorial
Drug-related harm: a complex and difficult concept to scale: **A. C. Parrott** 423

Review
The neuropsychology of ecstasy (MDMA) use: a quantitative review: **K. K. Zakzanis, Z. Campbell and D. Jovanovski** 427

Research Articles

Relationship between the cardiac response to acute intoxication and alcohol-induced subjective effects throughout the blood alcohol concentration curve: **C. Brunelle, S. P. Barrett and R. O. Pihl** 437

Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia: **A. M. Mortimer, E. Joyce, K. Balasubramaniam, P. C. Choudhary and P. T. Saleem for the SOLIANOL Study Group** 445

An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder: **F. Centorrino, A. L. Meyers, J. Ahl, S. L. Cincotta, L. Zun, A. H. Gulliver, B. J. Kinon and J. P. Houston** 455

HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis: **V. De Luca, D. J. Müller, R. Hwang, J. A. Lieberman, J. Volavka, H. Y. Meltzer and J. L. Kennedy** 463

Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder: **H. R. Winter, C. L. DeVane, C. Figueroa, D. J. Ennis, J. E. Hamer-Maansson, P. C. Davis and M. A. Smith** 469

Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: pragmatic randomized open-label comparison: **P. S. Matreja, D. K. Badyal, P. Khosla and R. S. Deswal** 477

Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients: **K. Miyamoto, R. Yoshimura, N. Ueda, A. Sugita, W. Umene, H. Hori, M. Mitoma and J. Nakamura** 483

Book Review

The Spectrum of Psychotic Disorders: Neurobiology, Etiology & Pathogenesis: **N. Garvey** 491

Current Awareness in Human Psychopharmacology 493

Issue No. 8 December 2007

Short Communication

No evidence for an association between G protein β3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia: **H.-J. Lee, S.-G. Kang, J.-W. Paik, M.-S. Lee, B.-H. Cho, Y.-M. Park, W. Kim, J.-E. Choi, I.-K. Jung, L. Kim and M.-S. Lee** 501

Research Articles

Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients: **W. Kissling, P. Glue, R. Medori and S. Simpson** 505

Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting: **C. Akkaya, A. Sarandol, S. Cangur and S. Kirli** 515

Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users: **C. Darredeau, S. P. Barrett, B. Jardin and R. O. Pihl** 529

Self reported sleep quality and cognitive performance in ecstasy users: **C. Montgomery, J. E. Fisk, M. Wareing and P. Murphy** 537

Review Article

Caffeine, sleep and wakefulness: implications of new understanding about withdrawal reversal: **J. E. James and M. A. Keane** 549

Research Articles

Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers: **D. O. Kennedy, P. A. Jackson, C. F. Haskell and A. B. Scholey** 559

Effects of substance P on memory and mood in healthy male subjects: **I. Herpfer, M. Katzev, B. Feige, B. L. Fiebich, U. Voderholzer and K. Lieb** 567

Current Awareness in Human Psychopharmacology 575

Author Index 583

Keyword Index 585

Volume Contents iii